secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lite Strategy, Inc. (LITS)
CIK:        0001262104
Form:       8-K
Filed at:   2024-09-19T23:59:59+00:00
Accession:  0000950170-24-108171
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MEI Pharma reports $38.3M cash; continues evaluating strategic alternatives
---------------------------------------------------------------------------

- Cash, cash equivalents, and short-term investments at June 30, 2024: $38.3 million, with no outstanding debt.
- Board commenced evaluation of strategic alternatives on July 22, 2024; Oppenheimer & Co. retained as exclusive financial adviser.
- Reduction-in-force commenced August 1, 2024, continuing in stages; clinical development of voruciclib discontinued.
- Options include out-licensing programs and M&A; company will not disclose developments unless completed or required.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1262104/000095017024108171/0000950170-24-108171-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1262104/000095017024108171/meip-20240919.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-108171

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer